NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	relapsed/refractory CD30-positive HL or sALCL
Date of first enrollment	07/10/2011
Target sample size	17
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : SGN-35 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	Major inclusion criteria include the following: 1) CD30-positive HL or sALCL 2) Patients who had PD during the standard chemo therapy OR who did not have CR/PR OR who had a recurrence or reprogression after the standard chemo therapy 3) Patients with HL must have been ineligible for, refused treatment by or previously received ASCT 4) Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1 5) Adequate hematologic, renal and liver function
Exclude criteria	Major exclusion criteria include the following: 1) Primary cutaneous ALCL 2) Uncontrolled diabetes 3) Patients with known cerebral/meningeal disease 4) Patients with history of allogeneic stem cell transplant 5) Patients with a history of another malignancy